BI 765064 SIRP α-antibody Phase I started

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRP α Antagonist Monoclonal Antibody,
BI 765063, in Patients with Advanced Solid TumorsFirst-in-class checkpoint inhibitor BI 765063 licensed to and being developed under a collaboration agreement between Boehringer Ingelheim and OSE ImmunotherapeuticsClinical Trial Authorization and dosing of the first patient triggers a total of €15 million milestone payments from Boehringer Ingelheim to OSE Immunotherapeutics

Source: Boehringer Ingelheim Corporate News - June 17, 2019 Category: Research Source Type: news